Gut microbiome dysbiosis in PCOS: from pathogenesis to microbiome-targeted therapies

• by Xinyun Du, Hao Su, Yuexi Huang, Jiani Liu, Qiaoying Li, Xuping Yang, Xuemei Tao, Rong Li

• April 13, 2026

Supreme Court extends mifepristone deadline

• by Theresa Gaffney

• May 12, 2026

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

• by Kathryn Wighton

• May 27, 2026

• 5 min

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

• by Kathryn Wighton

• May 21, 2026

• 2 min